Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
A:--
F: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
No matching data
Latest Views
Latest Views
Trending Topics
To quickly learn market dynamics and follow market focuses in 15 min.
In the world of mankind, there will not be a statement without any position, nor a remark without any purpose.
Inflation, exchange rates, and the economy shape the policy decisions of central banks; the attitudes and words of central bank officials also influence the actions of market traders.
Money makes the world go round and currency is a permanent commodity. The forex market is full of surprises and expectations.
Top Columnists
Enjoy exciting activities, right here at FastBull.
The latest breaking news and the global financial events.
I have 5 years of experience in financial analysis, especially in aspects of macro developments and medium and long-term trend judgment. My focus is maily on the developments of the Middle East, emerging markets, coal, wheat and other agricultural products.
BeingTrader chief Trading Coach & Speaker, 8+ years of experience in the forex market trading mainly XAUUSD, EUR/USD, GBP/USD, USD/JPY, and Crude Oil. A confident trader and analyst who aims to explore various opportunities and guide investors in the market. As an analyst I am looking to enhance the trader’s experience by supporting them with sufficient data and signals.
Latest Update
Risk Warning on Trading HK Stocks
Despite Hong Kong's robust legal and regulatory framework, its stock market still faces unique risks and challenges, such as currency fluctuations due to the Hong Kong dollar's peg to the US dollar and the impact of mainland China's policy changes and economic conditions on Hong Kong stocks.
HK Stock Trading Fees and Taxation
Trading costs in the Hong Kong stock market include transaction fees, stamp duty, settlement charges, and currency conversion fees for foreign investors. Additionally, taxes may apply based on local regulations.
HK Non-Essential Consumer Goods Industry
The Hong Kong stock market encompasses non-essential consumption sectors like automotive, education, tourism, catering, and apparel. Of the 643 listed companies, 35% are mainland Chinese, making up 65% of the total market capitalization. Thus, it's heavily influenced by the Chinese economy.
HK Real Estate Industry
In recent years, the real estate and construction sector's share in the Hong Kong stock index has notably decreased. Nevertheless, as of 2022, it retains around 10% market share, covering real estate development, construction engineering, investment, and property management.
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
View All
No data
Not Logged In
Log in to access more features
FastBull Membership
Not yet
Purchase
Log In
Sign Up
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
Teva Pharmaceutical (NYSE:TEVA) and Sanofi (NASDAQ:SNY) stocks were rising on Tuesday after the companies announced successful results of a phase 2 study involving the treatment of patients with ulcerative colitis (UC) and Crohn’s disease (CD).
Teva Pharmaceutical (NYSE:TEVA) and Sanofi (NASDAQ:SNY) stocks were rising on Tuesday after the companies announced successful results of a phase 2 study involving the treatment of patients with ulcerative colitis (UC) and Crohn’s disease (CD).
The study investigated duvakitug, a human monoclonal antibody targeting, for the treatment of moderate-to-severe inflammatory bowel disease (IBD). UC and CD are the two main types of IBD. The companies announced that the Phase 2b Relieve UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn’s disease (CD).
Specifically, 36.2% of low-dose patients and 47.8% of high-dose patients with UC treated with duvakitug achieved clinical remission compared to 20.45% on placebo.
Also, 26.1% of low-dose patients and 47.8% of high-dose patients with CD treated with duvakitug achieved endoscopic response compared to 13.0% on placebo.
Overall, duvakitug was generally well tolerated in both UC and CD with no safety signal identified.
“The results from the RELIEVE UCCD study have exceeded our expectations, and I am deeply moved by the potential for duvakitug to help treat and meaningfully improve the quality of life of people living with IBD,” Eric Hughes, MD, PhD, head of global R&D and chief medical officer at Teva, said. “These positive results reinforce Teva’s ability to develop and accelerate access to innovative medicines.”
Teva and Sanofi are co-developing Teva’s duvakitug for the treatment of UC and CD. Each company will equally share the development costs as well as the net profits and losses in major markets.
Teva will lead commercialization of the product in Europe, Israel and specified other countries. Further, Sanofi will lead commercialization in North America, Japan, other parts of Asia, and the rest of the world.
Sanofi will lead the Phase 3 clinical development program, pending regulatory approvals.
“These unprecedented results show that duvakitug could represent the next frontier in treating ulcerative colitis and Crohn’s disease. If the magnitude of effect persists in the Phase 3 program, we believe we will have a differentiated medicine for IBD patients who are in urgent need of new options,” Houman Ashrafian, MD, PhD, executive vice president, head of R&D at Sanofi, said.
Teva stock was the top gainer on the market Tuesday, rising 26% on the news to about $20 per share. The pharma stock has risen 99% year to date, fueled by rapidly rising revenue.
In the latest quarter, Teva generated $4.3 billion in revenue, a 13% year over year increase. It was buoyed by strong results for two of its drugs, Austedo and Ajovy, and its generics.
Specifically, Austedo saw a 28% increase in revenue to $435 million in the quarter, while Ajovy revenue increased 21% to $137 million. Its generics business saw 30% revenue growth in the U.S., 8% in Europe, and 13% in international markets in Q3. The third quarter results enabled Teva to boost its revenue outlook for fiscal 2024.
Further, the progression of the duvakitug IBD study, as well as a pending review of its biosimilar candidate to Prolia by the FDA and the European Medicines Agency (EMA), gives Teva a solid pipeline for increased sales going forward.
Analysts rate Teva stock as a solid buy, with a price target of $23 per share. That would be about an 11% increase. BofA Securities raised Teva’s price target to $25 per share after the study results were released, citing the potential for increased sales.
Sanofi stock was also rising Tuesday, up about 7% to $49 per share. The pharma stock is down about 1% year to date, trading at around $49 per share. Sanofi has a P/E ratio of 24 and a forward P/E of 10, giving it a fairly attractive valuation. The median price target is about $61 per share, giving it 24% potential upside over the next 12 months.
The US Dollar Index (DXY) trades with a mild negative bias near 106.85 during the early European trading hours on Wednesday. The speculation that the Federal Reserve (Fed) will adopt a more cautious stance on cutting interest rates might provide some support to the US Treasury bond yields and the US Dollar (USD).
The US Census Bureau revealed on Tuesday that Retail Sales in the US climbed by 0.7% MoM in November versus a 0.5% increase (revised from 0.4%) in October. This figure came in stronger than the expectation of a 0.5% increase. Meanwhile, US Industrial Production came in below the market consensus, declining by 0.1% MoM in November, compared to a fall of 0.4% (revised from -0.3%) in October. However, the US Retail Sales data had no impact on expectations that the Fed would reduce interest rates at its December meeting on Wednesday.
The US central bank is scheduled to announce its interest rate decision at its December meeting on Wednesday. The markets expect that the Fed will cut rates for the third time in a row, bringing the Federal Funds Rate lower to a target range of 4.25% to 4.50%. According to the CME FedWatch Tool, there is now a 97.1% odds of a 25 basis points (bps) rate cut, while the probability of maintaining current rates stands at 4.6%.
Jacob Channel, senior economist at LendingTree, said that the Fed will likely proceed with a 25 bps reduction at its upcoming meeting, but there may not be further cuts in the immediate future. Traders will take more cues from the Fed Chair Jerome Powell’s Press Conference and Summary of Economic Projections (dot-plot) after the meeting. If the Fed officials deliver the less dovish comments, this could lift the Greenback against its rivals. However, any signs of further Fed rate reduction could weigh on the USD.
USD/CHF extends its losses after pulling back from a six-month high of 0.8974, reached on Tuesday. The pair trades around 0.8920 during the Asian hours on Wednesday. Traders are bracing for a potential 25 basis point rate cut by the US Federal Reserve (Fed) later in the North American session.
According to the CME FedWatch tool, markets are now almost fully pricing in a quarter basis point cut at the Fed's December meeting. Additionally, traders will closely monitor Fed Chair Jerome Powell's press conference and Summary of Economic Projections (dot-plot) after the meeting.
On Tuesday, the US Census Bureau reported that US Retail Sales rose 0.7% MoM in November, compared to the 0.5% prior increase. Meanwhile, the Retail Sales Control Group increased 0.4% from the previous decline of 0.1%.
The Swiss Franc (CHF) came under pressure after the Swiss National Bank (SNB) unexpectedly cut its key interest rate by 50 basis points last week, surpassing expectations for a smaller reduction, as it seeks to address subdued inflation.
The SNB reaffirmed its commitment to maintaining price stability over the medium term, signaling readiness to adjust monetary policy if needed. The central bank noted that "underlying inflationary pressure has decreased again this quarter," with annual inflation declining from 1.1% in August to 0.7% in November, nearing the lower end of its target range of 0-2%.
Switzerland's State Secretariat for Economic Affairs (SECO) has revised its economic growth forecasts, projecting the Swiss economy to grow by 0.9% in 2023, down from the previous estimate of 1.2%. For 2024, the growth forecast has been adjusted to 1.5%, slightly lower than the earlier projection of 1.6%. The KOF Swiss Economic Institute forecasts growth of 1.4% in 2025 and 1.7% in 2026, anticipating weak foreign demand until mid-2025, followed by a gradual recovery.
What key factors drive the Swiss Franc?
The Swiss Franc (CHF) is Switzerland’s official currency. It is among the top ten most traded currencies globally, reaching volumes that well exceed the size of the Swiss economy. Its value is determined by the broad market sentiment, the country’s economic health or action taken by the Swiss National Bank (SNB), among other factors. Between 2011 and 2015, the Swiss Franc was pegged to the Euro (EUR). The peg was abruptly removed, resulting in a more than 20% increase in the Franc’s value, causing a turmoil in markets. Even though the peg isn’t in force anymore, CHF fortunes tend to be highly correlated with the Euro ones due to the high dependency of the Swiss economy on the neighboring Eurozone.
Why is the Swiss Franc considered a safe-haven currency?
The Swiss Franc (CHF) is considered a safe-haven asset, or a currency that investors tend to buy in times of market stress. This is due to the perceived status of Switzerland in the world: a stable economy, a strong export sector, big central bank reserves or a longstanding political stance towards neutrality in global conflicts make the country’s currency a good choice for investors fleeing from risks. Turbulent times are likely to strengthen CHF value against other currencies that are seen as more risky to invest in.
How do decisions of the Swiss National Bank impact the Swiss Franc?
The Swiss National Bank (SNB) meets four times a year – once every quarter, less than other major central banks – to decide on monetary policy. The bank aims for an annual inflation rate of less than 2%. When inflation is above target or forecasted to be above target in the foreseeable future, the bank will attempt to tame price growth by raising its policy rate. Higher interest rates are generally positive for the Swiss Franc (CHF) as they lead to higher yields, making the country a more attractive place for investors. On the contrary, lower interest rates tend to weaken CHF.
How does economic data influence the value of the Swiss Franc?
Macroeconomic data releases in Switzerland are key to assessing the state of the economy and can impact the Swiss Franc’s (CHF) valuation. The Swiss economy is broadly stable, but any sudden change in economic growth, inflation, current account or the central bank’s currency reserves have the potential to trigger moves in CHF. Generally, high economic growth, low unemployment and high confidence are good for CHF. Conversely, if economic data points to weakening momentum, CHF is likely to depreciate.
How does the Eurozone monetary policy affect the Swiss Franc?
As a small and open economy, Switzerland is heavily dependent on the health of the neighboring Eurozone economies. The broader European Union is Switzerland’s main economic partner and a key political ally, so macroeconomic and monetary policy stability in the Eurozone is essential for Switzerland and, thus, for the Swiss Franc (CHF). With such dependency, some models suggest that the correlation between the fortunes of the Euro (EUR) and the CHF is more than 90%, or close to perfect.
Slower price growth was broad based across the eight major components. The one exception was transportation costs which rose to 1.1% y/y, from 0.3% in October.
Shelter inflation has been a key challenge for Canadians for some time now and cooled in November to 4.6% y/y, from 4.8% y/y in October. Mortgage interest costs were a key factor, as the year-on-year increased slowed from 14.7% to 13.2% y/y in November. Unfortunately, rent inflation continues to heat up, rising 7.7% y/y in November, up from 7.3% y/y in October.
The Black Friday deals were particularly good this year, keeping goods inflation flat both on the month and versus a year ago. Deals were to be had on cellular services (-6.1% m/m), furniture, clothing, and particularly children’s clothing.
The impact of Taylor Swift’s Eras Tour in Toronto in November was seen in hotel prices, which had their largest November increase ever in Ontario. This drove higher prices for traveller accommodation at the national level (+8.7% y/y).
The Bank of Canada’s preferred “core” inflation measures were steady at 2.7% y/y on average, matching October’s pace.
November’s inflation data came in line with the Bank of Canada’s expectations for inflation to average close to 2% over the next couple of years. Headline was only a tenth cooler than expected, but this was mitigated by a lack of progress in the Bank of Canada’s Core inflation measures.
Our forecast calls for headline inflation to rise somewhat above the Bank’s 2% target next year as likely tariffs raise goods costs (see forecast). However, we don’t expect that this is high enough to dissuade the BoC from cutting interest rates further. With an America-First agenda south of the border, Canada’s economy faces a challenging backdrop, and lower interest rates are required for support. That said, at 3.25% on the overnight rate, we are now at the edge of “neutral” territory, further cuts are expected to come at a more measured pace next year.
SYDNEY (Dec 18): Australia's government on Wednesday trimmed its likely budget deficit for the current fiscal year, but flagged bigger shortfalls ahead due to "unavoidable spending" on health, cost-of-living relief and veterans care.
Facing a tough election next year, the centre-left Labor government said the economy had slowed under the weight of high interest rates and elevated inflation, but insisted public spending would help ensure a soft landing.
Recent data for the third quarter showed that without public investment in infrastructure and rebates on electricity costs, the economy would have been in recession.
In its Mid-Year Economic and Fiscal Outlook (MYEFO), the government still had to trim its forecast for economic growth in the current fiscal year to end June 2025 to 1.75%, down from 2.0% in its main Budget last May.
Wage growth was also marked down to 3.0% in a blow to government claims it would deliver faster pay gains than the Liberal National opposition.
The economic slowdown was enough for the Reserve Bank of Australia (RBA) last week to open the door to policy easing, having held interest rates at 4.35% for all of this year.
Treasurer Jim Chalmers on Wednesday suggested more cost of living relief could be on the way, on top of the tax cuts, electricity rebates, cheaper medicines and other policies the government has already delivered to date.
"From budget to budget, if we can afford to do more and there is a case to do more to help people with the cost of living, of course then we will consider that," Chalmers said in a press briefing.
All this government spending meant its budget was back in deficit after two years of rare surpluses, though the shortfall this year was not as large as first feared.
The Treasury projected a deficit of A$26.9 billion (US$17.04 billion or RM76.06 billion) for the current 2024/25 year. That compared with a forecast of A$28.3 billion in its main Budget last May.
From there, the red ink only gets worse due to A$25 billion in extra payments. The projected deficit for the three years to 2027/28 is now A$117 billion, or A$23 billion more than expected in May.
"The slippage in subsequent years is largely because of urgent, unavoidable or automatic increases in spending in areas like pensions, Medicare and medicines," Treasury said in a statement.
Expected tax revenues from companies have also been downgraded as subdued demand in China weighs on prices for some of Australia's main commodity exports, notably iron ore. It retained the long-term iron ore price assumption at US$60 per tonne by the third quarter 2025, compared with US$104 per tonne currently.
The government's net debt was now seen expanding to A$1.16 trillion by 2027/28, from an expected A$940 billion this year. At 36.7% of gross domestic product, net debt would still be low by international standards.
Estimated overseas migration has been revised up to 340,000 for the 2024/25, from 260,000, as the government struggled to bring migration to more sustainable levels.
White Label
Data API
Web Plug-ins
Poster Maker
Affiliate Program
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.